Results 61 to 70 of about 49,940 (198)

Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

Pediatric Rheumatology Online Journal, 2017
Background The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.
Ekaterina I. Alexeeva, Leyla S. Namazova-Baranova, Tatyana M. Bzarova, Saniya I. Valieva, Rina V. Denisova, Tatyana V. Sleptsova, Kseniya B. Isaeva, Alexandra M. Chomahidze, Nikolay I. Taibulatov, Anna N. Fetisova, Anna V. Karaseva, Alexandr A. Baranov   +11 more
doaj   +1 more source

Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study

The Journal of Dermatology, EarlyView.
ABSTRACT Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of
Chunghwan Ro, Ana Ormaza Vera, Waleed Adawi, Clinton W. Enos   +3 more
wiley   +1 more source

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

BMC Musculoskeletal Disorders, 2004
Background Variability in dosing and costs of biologics among patients with rheumatoid arthritis (RA) is of interest to healthcare descision-makers.
Smith Daniel, Gilbert Thomas D, Ollendorf Daniel A   +2 more
doaj  

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial

Pediatric Rheumatology Online Journal
Background Etanercept has been studied in doses up to 0.8 mg/kg/week (max 50 mg/week) in juvenile idiopathic arthritis (JIA) patients. In clinical practice higher doses are used off-label, but evidence regarding the relation with outcomes is lacking.
Bastiaan T. van Dijk, Sytske Anne Bergstra, J. Merlijn van den Berg, Dieneke Schonenberg-Meinema, Lisette W.A. van Suijlekom-Smit, Marion A.J. van Rossum, Yvonne Koopman-Keemink, Rebecca ten Cate, Cornelia F. Allaart, Daniëlle M.C. Brinkman, Petra C.E. Hissink Muller   +10 more
doaj   +1 more source

Etanercept In the treatment of AA-amyloidosis in juvenile rheumatoid arthritis

Научно-практическая ревматология, 2004
Objective. To study effect of etanercept, an antagonist of serum A amyloid production in the AA amyloidosis treatment in juvenile idiopathic arthritis (JIA). Material and methods.
H Mihels
doaj   +1 more source

Clinical Images: Bone Buds as Precursors to Ankylosis in Axial Spondyloarthritis

Arthritis &Rheumatology, EarlyView.
Lilach Shkolnik Arad, Gleb Slobodin
wiley   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice

Mediators of Inflammation, 2019
In the present study, we investigated the effects and mechanisms of action of a combined treatment with etanercept, a soluble tumor necrosis factor receptor (p75) Fc fusion protein, and tacrolimus, a calcineurin inhibitor on the progression of arthritis ...
Iwao Seki, Miwa Takai-Imamura, Tomomi Kohara-Tanaka, Satoshi Shirae, Minoru Sasano, Hiroaki Matsuno, Hiroyuki Aono   +6 more
doaj   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, EarlyView.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source